BioGeneration Ventures

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

Like Benjamin Franklin knotting a key to a kite in a lightning storm, today’s AI researchers are unlocking technology that is reshaping our world. From quantum neural networks and transformers for NLP, to AI for drug discovery, the path to future innovations and commercialization is charted by a small subset of the global technology talent pool, the elite AI researchers. Coalescing around the pioneers of AI, including Toronto’s “godfather of deep learning” Geoffrey Hinton, this AI talent pool has laid the foundations for innovation and rapid commercialization. Radical is both a product of the Canada AI ecosystem and one of its architects. Radical founders Jordan Jacobs and Tomi Poutanen helped co-author the world’s first national AI strategy and conceived of and co-founded the Vector Institute for Artificial Intelligence, alongside Geoffrey Hinton, Ed Clark and others in 2017. Vector began with 8 faculty and is now home to over 1700 of the world’s top AI researchers. Before Radical, Jordan and Tomi founded Milq in 2011 and then spun-out Layer 6 AI in 2016, an AI prediction platform company later acquired by TD Bank, where they became co-Chief AI Officers. As founders, ecosystem builders and investors, the Radical team has played an active role in nurturing the next generation of AI innovation and commercialization. Just as Thomas Edison would build upon Franklin’s discoveries, now is the moment to capitalize on the opportunity afforded by innovations in AI. Every facet of our economy and lives stand to benefit from breakthroughs in AI. Like today’s electrical grid, AI will soon power nearly every human interaction with technology. Lightning to light bulb. That is the transformative moment we are investing in.

Since 2001, St. Louis nonprofit BioSTL has laid the foundation for the region's​ innovation economy with a comprehensive set of transformational programs that advance St. Louis’ leadership in solving important world challenges in agriculture, medicine, healthcare, and other technology areas. BioSTL has introduced nationally-acclaimed initiatives in startup creation and investment (BioGenerator), strategic business attraction (GlobalSTL), physical environment (including the Cortex Innovation District and BioGenerator Labs), entrepreneur support, seed and venture capital, a diverse and inclusive workforce, and public policy. Vision: St. Louis will be recognized globally as a leading center for bioscience research and commercialization with a vibrant entrepreneurial startup community that is a magnet for attracting talented people and enterprises. Success will generate quality jobs for St. Louis in a high-growth industry and will enhance regional prosperity by attracting substantial investment and revenues from outside the region.